Conclusions Presented by: Sant Chawla, M.D. •Aldoxorubicin significantly prolonged progression-free survival in North American and L-sarcoma subjects compared to standard tx. •Aldoxorubicin, given at 350 mg/m2/cycle, has minimal or no cardiotoxicity up to 40 cycles, compared to doxorubicin. •The non-cardiac grade 3/4 AEs of aldoxorubicin were similar to doxorubicin despite exposure to 3-4 times the doxorubicin dose. •Taken together, aldoxorubicin may be a superior anthracycline for treating advanced soft tissue sarcoma. •Finally, aldoxorubicin is a good alternative vs standard therapies for treatment of relapsed or refractory metastatic soft tissue sarcoma
|